Home / Resource Library / Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Study investigated the long term safety of ibrutinib for treating CLL across three major clinical trials.